Aptinyx's lead drug makes cut in small fi­bromyal­gia tri­al, set­ting the stage for larg­er chron­ic pain study

Four months ago, its lead drug fell short of hit­ting sta­tis­ti­cal sig­nif­i­cance in a di­a­bet­ic pe­riph­er­al neu­ropa­thy (DPN) study. On Mon­day, the new­ly-pub­lic Aptinyx re­vealed the ex­per­i­men­tal treat­ment has scored in a small mid-stage fi­bromyal­gia tri­al, paving the way for a larg­er study to be­gin in the sec­ond half of this year.

The drug — dubbed NYX-2925 — was de­vel­oped by the Evanston, IL-based biotech $AP­TX that went pub­lic last Ju­ly bank­ing on its ap­proach to mod­u­late NM­DA re­cep­tors, which are cru­cial to brain and ner­vous sys­tem func­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER